49 /100
MEDIUM RISK
Score updated Jul 14, 2026

GOSS — Gossamer Bio, Inc. Dilution Risk Tracker

Track GOSS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track GOSS — Get alerts when the score changes →

As of July 14, 2026, Gossamer Bio, Inc. (GOSS) has a DilutionWatch DilutionScore of 49/100, rated MEDIUM dilution risk. Gossamer Bio, Inc. has a market capitalization of $54.19M, 234.70M shares outstanding, 193 institutional holders tracked. Key dilution vectors include 32.47M outstanding warrants, approximately 6 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
65
📊 Float Risk
17
⚠️ Warrant Exposure
50
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
40%
🔄 Reverse Split 65%
• 50-day avg $0.34 below $1 exchange minimum
• 6 months cash with weak price
💰 Capital Raise 15%
• Under 12 months cash (6mo)
📜 Warrant Exercise 15%
• Warrant overhang: 13.8% of shares outstanding
🔔 Track GOSS — Get forecast alerts →

💹 Market Data

Market Cap$54.19M
Shares Outstanding234.70M
Float227.18M
Cash$99.22M
Debt$11.61M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 3.1% shares (2026Q1 vs prior)
193 institutional holders · 203.27M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 18.79M shares
#2 Kalehua Capital Management LLC 17.71M shares
#3 BlackRock, Inc. 16.83M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest53.70M
Days to Cover3.2
% of Float23.6%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2022
Form 4 INSIDER TRANSACTION Jan 02, 2026
Form 4 INSIDER TRANSACTION Jan 02, 2026
Form 4 INSIDER TRANSACTION Jan 02, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for GOSS Shareholders

Gossamer Bio, Inc. (GOSS) has a DilutionScore of 49/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch tracks 32.5M outstanding warrants for GOSS. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: GOSS has approximately 6 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for GOSS in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for GOSS alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →
Track GOSS Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking GOSS — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for GOSS
📊 GOSS FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 GOSS Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.